Neboglamine Explained

Neboglamine (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence.[1] [2] [3] [4] [5] [6] It shows cognition- and memory-enhancing effects in animal models.[7] [8] [9] As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.[10]

See also

External links

Notes and References

  1. Chiusaroli R, Garofalo P, Espinoza S, Neri E, Caselli G, Lanza M . Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat . Pharmacological Research . 61 . 5 . 430–6 . May 2010 . 20045056 . 10.1016/j.phrs.2009.12.010 .
  2. Kantrowitz J, Javitt DC . Glutamatergic transmission in schizophrenia: from basic research to clinical practice . Current Opinion in Psychiatry . 25 . 2 . 96–102 . March 2012 . 22297716 . 5224527 . 10.1097/YCO.0b013e32835035b2 .
  3. Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine. 28. 5. 2014. 265–271. 1178-2595. 10.1007/s40290-014-0070-6. 8513976.
  4. Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC . Novel NMDA receptor modulators: an update . Expert Opinion on Therapeutic Patents . 22 . 11 . 1337–52 . November 2012 . 23009122 . 3677696 . 10.1517/13543776.2012.728587 .
  5. Zink M, Correll CU . Glutamatergic agents for schizophrenia: current evidence and perspectives . Expert Review of Clinical Pharmacology . 8 . 3 . 335–52 . May 2015 . 25916667 . 10.1586/17512433.2015.1040393 . 39547774 .
  6. Köster LS, Carbon M, Correll CU . Emerging drugs for schizophrenia: an update . Expert Opinion on Emerging Drugs . 19 . 4 . 511–31 . December 2014 . 25234340 . 10.1517/14728214.2014.958148 . 42729570 .
  7. Garofalo P, Colombo S, Lanza M, Revel L, Makovec F . CR 2249: a new putative memory enhancer. Behavioural studies on learning and memory in rats and mice . The Journal of Pharmacy and Pharmacology . 48 . 12 . 1290–7 . December 1996 . 9004193 . 10.1111/j.2042-7158.1996.tb03938.x . 34902435 . free .
  8. Lanza M, Bonnafous C, Colombo S, Revel L, Makovec F . Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex . Neuropharmacology . 36 . 8 . 1057–64 . August 1997 . 9294970 . 10.1016/S0028-3908(97)00092-0 . 11958361 .
  9. Lanza M, Makovec F . Cognition Enhancing Profile of CR 2249, a New NMDA-Glycine Site Modulator. CNS Drug Reviews. 3. 3. 1997. 245–259. 1080-563X. 10.1111/j.1527-3458.1997.tb00326.x.
  10. Web site: Neboglamine . AdisInsight . 2015-06-10.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Neboglamine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.